Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ELAVL1 | Q15717 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20451451 | 0.81 | HTR6 (0.56) | HTR6L3MBTL1CA12CA9TDO2 | |
| SCHEMBL18498711 | 0.80 | HTR6 (0.55) | HTR6L3MBTL1CA12CA9CA1 | |
| SCHEMBL16990428 | 0.79 | HTR6 (0.55) | HTR6L3MBTL1CA12CA9TDO2 | |
| SCHEMBL16990291 | 0.78 | HTR6 (0.50) | HTR6L3MBTL1CA12CA9TDO2 | |
| SCHEMBL17096727 | 0.77 | HTR6 (0.52) | HTR6L3MBTL1CA12CA9CA1 | |
| SCHEMBL16990273 | 0.76 | HTR6 (0.51) | HTR6L3MBTL1CA12CA9CA1 | |
| SCHEMBL17097054 | 0.76 | HTR6 (0.48) | HTR6L3MBTL1CA12CA9CA1 | |
| SCHEMBL16698105 | 0.76 | PDPK1 (0.54) | HTR6L3MBTL1CA12CA9CA1 | |
| SCHEMBL16990238 | 0.76 | HTR6 (0.50) | HTR6L3MBTL1CA12CA9CA1 | |
| SCHEMBL16990265 | 0.76 | HTR6 (0.50) | HTR6L3MBTL1CA12CA9TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758505-B2 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS (BE) | 2017-09-12 | — | — | US | disclosed |
| EP-3105225-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121812-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 61/4885L3MBTL1 4034/4885CA12 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.